Kido K, Shimizu M, Shiga T, et al. - Researchers analyzed relevant studies identified from MEDLINE, Embase, Google Scholar, Web of Science, and Cochrane Library database, to compare direct oral anticoagulants (DOACs) vs warfarin among morbidly obese patients suffering from atrial fibrillation (AF) as well as to optimize an anticoagulation therapy in the population. They performed a meta-analysis involving overall 5 studies for the event rate of stroke or systemic embolism (SE) and 4 for major bleeding. According to the findings, DOAC and warfarin groups did not differ statistically significantly in terms of stroke or SE event rate. A significant link of DOAC use with a lower major bleeding event rate was revealed, relative to the warfarin group. Overall, experts recommended considering DOACs as an oral anticoagulant for preventing stroke or SE among morbidly obese patients encountering AF.